Drug Profile


Alternative Names: BAY 102; BAY-1021189; MK-1242

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase I Coronary artery disease

Most Recent Events

  • 18 Apr 2017 Phase-III clinical trials in Chronic heart failure in Ukraine, Turkey, South Africa, United Kingdom, Taiwan, Switzerland, Sweden, Singapore, Russia, Puerto Rico, Poland, Philippines, Norway, New Zealand, Netherlands, Mexico, Malaysia, South Korea, Japan, Italy, Ireland, Hong Kong, Greece, Finland, France, Denmark, Czech Republic, Colombia, Chile, Canada, Belgium, Austria, Australia, USA (PO) (NCT02861534)
  • 28 Feb 2017 Merck has patent protection for vericiguat in USA (Merck Annual report 2016)
  • 30 Sep 2016 Phase-III clinical trials in Chronic heart failure in Germany, Hungary and Spain (PO) (EudraCT2016-000671-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top